{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T14:53:14Z","timestamp":1785941594280,"version":"3.56.0"},"reference-count":61,"publisher":"MDPI AG","issue":"21","license":[{"start":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T00:00:00Z","timestamp":1698192000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Novel cellular immunotherapies such as T-cell engaging antibodies (TCEAbs) are changing the landscape of treatment for diffuse large B cell lymphoma (DLBCL), especially in the relapsed\/refractory (R\/R) setting. TCEAbs harness the power of the host immune system to induce killing of tumor cells by binding to both the tumor antigen and the T-cell receptor. Since the approval of blinatumomab for R\/R acute lymphoblastic leukemia, there has been significant development in novel TCEAbs. Many of these novel TCEAbs have shown promising effectiveness in R\/R DLBCL, with favorable response rates including complete remissions, even in heavily pretreated patients. There are unique therapy-related toxicities with TCEAbs, namely cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity (ICANS), and it is important to both recognize and manage these side effects appropriately. This review examines the development and mechanism of action of these TCEAbs, and the available published data from clinical trials. Their role in the treatment of DLBCL, the management of therapy-related adverse events, and the mechanisms of resistance will also be discussed.<\/jats:p>","DOI":"10.3390\/jcm12216737","type":"journal-article","created":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T06:19:58Z","timestamp":1698214798000},"page":"6737","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["T-Cell Engaging Antibodies in Diffuse Large B Cell Lymphoma\u2014An Update"],"prefix":"10.3390","volume":"12","author":[{"given":"Shalini","family":"Balendran","sequence":"first","affiliation":[{"name":"Alfred Health, Melbourne, VIC 3004, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantine","family":"Tam","sequence":"additional","affiliation":[{"name":"Alfred Health, Melbourne, VIC 3004, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Ku","sequence":"additional","affiliation":[{"name":"St. Vincent\u2019s Hospital, Melbourne, Fitzroy, VIC 3065, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,10,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1182\/blood-2005-06-2508","article-title":"Lymphoma incidence patterns by WHO subtype in the United States, 1992\u20132001","volume":"107","author":"Morton","year":"2006","journal-title":"Blood"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: Results from the international SCHOLAR-1 study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1080\/10428194.2018.1564828","article-title":"Treatment of aggressive B-cell non-Hodgkin lymphoma beyond frontline therapy in patients not eligible for stem cell transplantation: A structured review","volume":"60","author":"Salles","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1080\/10428190310001653736","article-title":"Outcome of elderly patients with aggressive Non-Hodgkin\u2019s lymphoma refractory to or relapsing after first-line CHOP or CHOP-like chemotherapy: A low probability of cure","volume":"45","author":"Jabbour","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): A multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma","volume":"386","author":"Locke","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa2116596","article-title":"Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma","volume":"386","author":"Bishop","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.drudis.2015.02.008","article-title":"Bispecific antibodies","volume":"20","author":"Kontermann","year":"2015","journal-title":"Drug Discov. Today"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1002\/cpt.1396","article-title":"Bispecific Antibodies in the Treatment of Hematologic Malignancies","volume":"106","author":"Duell","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e2104504118","DOI":"10.1073\/pnas.2104504118","article-title":"Genetic mechanisms of HLA-I loss and immune escape in diffuse large B cell lymphoma","volume":"118","author":"Fangazio","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1038\/s41416-020-01225-5","article-title":"Overcoming the challenges associated with CD3+ T-cell redirection in cancer","volume":"124","author":"Singh","year":"2021","journal-title":"Br. J. Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1182\/blood.2021011994","article-title":"Bispecific antibodies for the treatment of B-cell lymphoma: Promises, unknowns, and opportunities","volume":"141","author":"Falchi","year":"2023","journal-title":"Blood"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Tavarozzi, R., and Manzato, E. (2022). The Role of Bispecific Antibodies in Non-Hodgkin\u2019s Lymphoma: From Structure to Prospective Clinical Use. Antibodies, 11.","DOI":"10.3390\/antib11010016"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Bates, A., and Power, C.A. (2019). David vs. Goliath: The Structure, Function, and Clinical Prospects of Antibody Fragments. Antibodies, 8.","DOI":"10.3390\/antib8020028"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Papageorgiou, S.G., Thomopoulos, T.P., Liaskas, A., and Vassilakopoulos, T.P. (2022). Monoclonal Antibodies in the Treatment of Diffuse Large B-Cell Lymphoma: Moving beyond Rituximab. Cancers, 14.","DOI":"10.3390\/cancers14081917"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/s41423-020-0417-8","article-title":"Challenges and strategies for next-generation bispecific antibody-based antitumor therapeutics","volume":"17","author":"Li","year":"2020","journal-title":"Cell Mol. Immunol."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Salvaris, R., Ong, J., and Gregory, G.P. (2021). Bispecific Antibodies: A Review of Development, Clinical Efficacy and Toxicity in B-Cell Lymphomas. J. Pers. Med., 11.","DOI":"10.3390\/jpm11050355"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1182\/blood-2022-168739","article-title":"Characterization of JNJ-80948543, a Novel CD79bxCD20xCD3 Trispecific T-Cell Redirecting Antibody for the Treatment of B-Cell Non-Hodgkin Lymphoma","volume":"140","author":"Kuchnio","year":"2022","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1182\/blood-2022-168904","article-title":"PIT565, a First-in-Class Anti-CD19, Anti-CD3, Anti-CD2 Trispecific Antibody for the Treatment of B Cell Malignancies","volume":"140","author":"Lu","year":"2022","journal-title":"Blood"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1182\/blood-2017-08-798322","article-title":"Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia","volume":"131","author":"Gokbuget","year":"2018","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1182\/bloodadvances.2019000025","article-title":"Long-term outcome of patients with relapsed\/refractory B-cell non-Hodgkin lymphoma treated with blinatumomab","volume":"3","author":"Dufner","year":"2019","journal-title":"Blood Adv."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1080\/10428194.2020.1759055","article-title":"Open-Label, phase 2 study of blinatumomab as second salvage therapy in adults with relapsed\/refractory aggressive B-cell non-Hodgkin lymphoma","volume":"61","author":"Coyle","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1182\/blood-2015-06-651380","article-title":"Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed\/refractory diffuse large B-cell lymphoma","volume":"127","author":"Viardot","year":"2016","journal-title":"Blood"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1182\/blood-2019-124254","article-title":"Blinatumomab\/Lenalidomide in Relapsed\/Refractory Non-Hodgkin\u2019s Lymphoma: A Phase I California Cancer Consortium Study of Safety, Efficacy and Immune Correlative Analysis","volume":"134","author":"Poh","year":"2019","journal-title":"Blood"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1182\/blood-2020-142464","article-title":"Blinatumomab Consolidation Post Autologous Hematopoietic Stem Cell Transplantation in Patients with Diffuse Large B Cell Lymphoma","volume":"136","author":"Ghobadi","year":"2020","journal-title":"Blood"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1200\/JCO.21.00931","article-title":"Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients with Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study","volume":"40","author":"Budde","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/S0140-6736(21)00889-8","article-title":"Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: An open-label, phase 1\/2 study","volume":"398","author":"Hutchings","year":"2021","journal-title":"Lancet"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1200\/JCO.22.01725","article-title":"Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I\/II Trial","volume":"41","author":"Thieblemont","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1002\/hon.3163_94","article-title":"Subcutaneous epcoritamab induces deep, durable complete remissions in relapsed\/refractory large B-cell lymphoma: Longer follow-up from the pivotal epcore NHL-1 trial","volume":"41","author":"Thieblemont","year":"2023","journal-title":"Hematol. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"4785","DOI":"10.1158\/1078-0432.CCR-18-0455","article-title":"CD20-TCB with Obinutuzumab Pretreatment as Next-Generation Treatment of Hematologic Malignancies","volume":"24","author":"Bacac","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","article-title":"Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"387","author":"Dickinson","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/hon.3163_92","article-title":"Glofitamab plus polatuzumab vedotin demonstrates durable responses and a manageable safety profile in patients with relapsed\/refractory diffuse large B-cell lymphoma","volume":"41","author":"Hutchings","year":"2023","journal-title":"Hematol. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"17943","DOI":"10.1038\/srep17943","article-title":"A novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse tumor models and cynomolgus monkeys","volume":"5","author":"Smith","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e327","DOI":"10.1016\/S2352-3026(22)00072-2","article-title":"Odronextamab, a human CD20xCD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): Results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial","volume":"9","author":"Bannerji","year":"2022","journal-title":"Lancet Haematol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/hon.3163_93","article-title":"Odronextamab in patients with relapsed\/refractory diffuse large B-cell lymphoma (DLBCL): Results from a prespecified analysis of the pivotal phase II study ELM-2","volume":"41","author":"Poon","year":"2023","journal-title":"Hematol. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"9470","DOI":"10.1182\/blood-2022-159586","article-title":"A Phase 1 Study of Plamotamab, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed\/Refractory Non-Hodgkin\u2019s Lymphoma: Recommended Dose Safety\/Efficacy Update and Escalation Exposure-Response Analysis","volume":"140","author":"Patel","year":"2022","journal-title":"Blood"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"12066","DOI":"10.1182\/blood-2022-158042","article-title":"Phase 2 Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Plamotamab Combined with Tafasitamab (Tafa) + Lenalidomide (Len) Vs Tafa+Len in Relapsed or Refractory DLBCL","volume":"140","author":"Patel","year":"2022","journal-title":"Blood"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa2115304","article-title":"Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma","volume":"386","author":"Tilly","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","article-title":"Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): Results from an interim analysis of an open-label, randomised, phase 3 trial","volume":"399","author":"Kamdar","year":"2022","journal-title":"Lancet"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol. Blood Marrow Transpl."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","article-title":"Cytokine release syndrome","volume":"6","author":"Godel","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1182\/blood.V94.7.2217.419k02_2217_2224","article-title":"Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8)","volume":"94","author":"Winkler","year":"1999","journal-title":"Blood"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","article-title":"Toxicities of chimeric antigen receptor T cells: Recognition and management","volume":"127","author":"Brudno","year":"2016","journal-title":"Blood"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"4017","DOI":"10.1182\/blood-2014-12-580068","article-title":"CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia","volume":"125","author":"Maude","year":"2015","journal-title":"Blood"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1200\/JCO.20.03175","article-title":"Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial","volume":"39","author":"Hutchings","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","article-title":"Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells","volume":"7","author":"Gust","year":"2017","journal-title":"Cancer Discov."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1158\/2159-8290.CD-17-1319","article-title":"Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia","volume":"8","author":"Santomasso","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"3280","DOI":"10.4049\/jimmunol.172.5.3280","article-title":"Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia","volume":"172","author":"Kennedy","year":"2004","journal-title":"J. Immunol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1046\/j.1365-2141.2001.03019.x","article-title":"Loss of CD20 expression following treatment with rituximab (chimaeric monoclonal anti-CD20): A retrospective cohort analysis","volume":"114","author":"Foran","year":"2001","journal-title":"Br. J. Haematol."},{"key":"ref_56","first-page":"10","article-title":"Baseline Biomarkers of T-Cell Function Correlate with Clinical Responses to Odronextamab (REGN1979), and Loss of CD20 Target Antigen Expression Identified As a Mechanism of Treatment Resistance","volume":"136","author":"Fiaschi","year":"2020","journal-title":"Blood"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1182\/bloodadvances.2021005954","article-title":"Pharmacodynamics and molecular correlates of response to glofitamab in relapsed\/refractory non-Hodgkin lymphoma","volume":"6","author":"Broske","year":"2022","journal-title":"Blood Adv."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1182\/blood.2018889931","article-title":"PD-1\/PD-L1 immune checkpoint and p53 loss facilitate tumor progression in activated B-cell diffuse large B-cell lymphomas","volume":"133","author":"Pascual","year":"2019","journal-title":"Blood"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1200\/JCO.21.02143","article-title":"Impact of TP53 Genomic Alterations in Large B-Cell Lymphoma Treated with CD19-Chimeric Antigen Receptor T-Cell Therapy","volume":"40","author":"Shouval","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.4049\/jimmunol.1402382","article-title":"Elevation of c-MYC disrupts HLA class II-mediated immune recognition of human B cell tumors","volume":"194","author":"God","year":"2015","journal-title":"J. Immunol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1182\/blood-2021-153355","article-title":"A Phase 1 Dose Escalation Study of Igm-2323, a Novel Anti-CD20 x Anti-CD3 IgM T Cell Engager (TCE) in Patients with Advanced B-Cell Malignancies","volume":"138","author":"Budde","year":"2021","journal-title":"Blood"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/21\/6737\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:11:23Z","timestamp":1760130683000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/21\/6737"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,25]]},"references-count":61,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2023,11]]}},"alternative-id":["jcm12216737"],"URL":"https:\/\/doi.org\/10.3390\/jcm12216737","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,25]]}}}